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Abstract
Complex regional pain syndrome (CRPS) is characterized by continuous pain that is often accompanied by sensory, motor, 
vasomotor, sudomotor, and trophic disturbances. If left untreated, it can have a significant impact on the quality of life of 
patients. The diagnosis of CRPS is currently based on a set of relatively subjective clinical criteria: the New International 
Association for the Study of Pain clinical diagnostic criteria for CRPS. There are still no objective laboratory tests to diagnose 
CRPS and there is a great need for simple, objective, and easily measurable biomarkers in the diagnosis and management 
of this disease. In this review, we discuss the role of inflammation in the multi-mechanism pathophysiology of CRPS and 
highlight the application of potential biomarkers of inflammation in the diagnosis and management of this disease.
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Key Points 
Neurogenic inflammation, neuroinflammation and 
immune dysregulation contribute to inflammation in 
complex regional pain syndrome (CRPS).
Biomarkers reflecting these inflammatory mechanisms 
could aid in both the diagnosis and management of 
CRPS.
Further research is needed to validate these biomarkers 
of inflammation in CRPS.
1 Introduction
Complex regional pain syndrome (CRPS) is a painful dis-
ease of the extremities that is usually initiated by tissue 
damage, e.g., following fracture or surgery [1, 2]. It is char-
acterized by continuous pain that is disproportionate to the 
inciting event, and which can be accompanied by sensory, 
motor, vasomotor, sudomotor, and trophic disturbances [3]. 
The incidence of CRPS has been reported to vary between 
5.5 and 26.2 per 100,000 person-years and women are 
reported to be affected more often than men [1, 2].
Currently, the disease is diagnosed using a set of clini-
cal criteria: the new International Association for the Study 
of Pain (IASP) clinical diagnostic criteria for CRPS [3]. 
There is still no objective test available for diagnosis and/
or management of this disease. Additional testing, such as 
blood tests and radiography, are only used to exclude other 
diseases, such as rheumatic diseases, in the differential diag-
nosis [4]. Once CRPS is diagnosed, treatment is preferably 
conducted by a multidisciplinary team consisting of pain 
physicians, physiatrists, physiotherapists, and psycholo-
gists. Because CRPS is considered to have a multi-mech-
anism pathophysiology, it is advised that the treatment be 
conducted in a mechanism-based manner: it should target 
the underlying pathophysiological mechanisms of disease 
in each unique CRPS case [5, 6].
If left untreated, CRPS can lead to a debilitating loss of 
function of the affected extremity and can have a significant 
social impact on the life of patients [7]. It is therefore impor-
tant that this disease is diagnosed early and treated with 
appropriate mechanism-based therapies. However, early 
diagnosis and therapy selection are often hampered by the 
aforementioned lack of objective tests. Currently, physicians 
have to rely on subjective symptoms reported by patients 
and relatively subjective signs observed during physical 
examination for diagnosis and management of CRPS. This 
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subjectivity of symptoms and signs, which is often accom-
panied by a discrepancy between the symptoms and signs, 
leads to various diagnostic and therapeutic challenges for cli-
nicians, such as delayed diagnosis and inappropriate selec-
tion of therapies. To make these matters more complicated, 
CRPS is a disease with a heterogeneous clinical presentation 
and there may be various disease subtypes with their own 
specific phenotype [8–10]. These matters therefore not only 
complicate diagnosis of this disease but also the selection of 
therapies based on the underlying pathophysiological mech-
anisms as, at present, these underlying mechanisms are also 
deduced from the relatively subjective, and often discrepant, 
symptoms and signs.
These diagnostic and therapeutic challenges highlight the 
need for simple, objective, and easily measurable biomarkers 
in the diagnosis and management of CRPS. In this review, 
we aim to highlight the application of potential biomarkers, 
specifically biomarkers of inflammation, in the diagnosis 
and management of CRPS. For reasons of clarity, we have 
mostly limited ourselves to biomarkers that can be measured 
in blood and skin.
2  Pathophysiology of Complex Regional 
Pain Syndrome (CRPS)
It has been generally accepted that multiple pathophysiologi-
cal mechanisms contribute to CRPS. The following mecha-
nisms have been implicated in the onset and maintenance of 
CRPS: inflammation, peripheral and central sensitization, 
altered sympathetic nervous system function, changes in 
circulating catecholamine levels, endothelial dysfunction, 
cortical reorganization, and immune-acquired, genetic and 
psychological factors [11, 12]. However, it is as yet unclear 
how and to what extent each of these mechanisms cause and 
maintain this disease.
In this article, we focus on the role of biomarkers of 
inflammation in the diagnosis and management of CPRS. 
We summarize the current knowledge on inflammation in 
CRPS as well as the related symptoms and signs. For further 
information on the role of other mechanisms in CRPS, we 
refer the reader to more extensive reviews [11, 13–15].
In CRPS, neurogenic inflammation, neuroinflammation, 
and dysregulation of the immune system have all been impli-
cated as a source of inflammation. Peripheral neurogenic 
inflammation has long been implicated in the pathophysiol-
ogy of CRPS [16]. In peripheral neurogenic inflammation, 
primary afferent sensory neurons release neuropeptides that 
cause cutaneous vasodilation (mainly through calcitonin 
gene-related peptide [CGRP]), changes in vascular perme-
ability (mainly through substance P [SP]), increased protein 
extravasation, and increased leukocyte recruitment [17, 18]. 
Weber et al. [19] conducted a study using transcutaneous 
electrical stimulation via intradermal microdialysis capillar-
ies and found significantly increased axon reflex vasodilation 
in the affected extremity of CRPS patients compared with 
healthy controls. This study further found increased pro-
tein extravasation in the affected extremity of these CRPS 
patients [19]. These findings suggest an increased release of 
neuropeptides such as CGRP and SP by activated sensory 
neurons in CRPS patients and thus point towards facilitated 
neurogenic inflammation in CRPS [19]. This increased neu-
ropeptide release may also account for symptoms such as 
allodynia, hyperalgesia, edema, vasodilation, and trophic 
abnormalities that are seen in CRPS patients [19, 20].
Besides neurogenic inflammation, recent studies have 
provided evidence supporting a role for neuroinflammation 
in CRPS [21, 22]. Neuroinflammation refers to inflammation 
occurring within the nervous system (central nervous system 
and/or peripheral nervous system) that is characterized by 
glial cell activation leading to an increased production of 
pro-inflammatory cytokines and chemokines [23]. Neuro-
inflammation can be initiated by various forms of trauma 
and surgery, and it has also been suggested that it can be 
caused by increased neuronal activity of primary afferent 
nerve fibers and/or higher-order neurons [23, 24]. This latter 
phenomenon has been coined ‘neurogenic neuroinflamma-
tion’ and has also been implicated in CRPS [20, 24]. Neu-
roinflammation can lead to various adverse effects, such as 
a transition from acute to chronic pain and maintenance of 
chronic pain [23]. This chronic pain is established via central 
sensitization, which is induced and maintained by central 
cytokines, chemokines, and glia-produced mediators [23]. 
Central sensitization is characterized by pain hypersensi-
tivity and manifests clinically as dynamic tactile allodynia, 
secondary punctuate and/or pressure hyperalgesia, temporal 
summation, and sensory after sensations [25]. Symptoms 
of central sensitization have also been described in CRPS 
[25–28] and have been attributed to a sensitization of the 
nociceptive system due to ongoing pain and, therefore, to 
continuous nociceptive input [11, 29]. As neuroinflamma-
tion seems to drive central sensitization, and studies now 
suggest neuroinflammation may play a role in CRPS, it is 
possible that part of the symptoms of CRPS that are attrib-
uted to central sensitization can be caused not only by con-
tinuous nociceptive input but also by neuroinflammation 
[21–23]. Neuroinflammatory findings in CRPS are new and 
need to be studied in further detail, yet neuroinflammation 
represents an interesting therapeutic target in patients with 
symptoms and signs of central sensitization.
Although peripheral neurogenic inflammation has long 
been implicated in CRPS, it is only in recent years that 
evidence to support involvement of the immune system in 
CRPS has grown. Until recently, the involvement of the 
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immune system in CRPS was a topic of intense debate: 
though classic signs of inflammation such as calor, dolor, 
rubor, tumor, and functio laesa were often seen in CRPS 
patients, classic systemic markers of inflammation such as 
C-reactive protein and white blood cells were mostly within 
the normal range in patients [30–32]. Because of a lack of 
objective evidence for immune system involvement, a dys-
regulation of the immune system was disregarded for years 
as a possible pathophysiological mechanism in CRPS. In 
recent years, however, due to a better understanding of the 
disease and improved research techniques, it has been pos-
sible to identify a role of the immune system in CRPS. Sev-
eral lines of evidence now support a role for dysregulated 
immune activation and subsequent inflammation in CRPS: 
(1) increased levels of the pro-inflammatory cytokines tumor 
necrosis factor (TNF)-α and interleukin (IL)-6 have been 
found in blister fluid of CRPS-affected extremities compared 
with clinically uninvolved contralateral extremities [33]; 
(2) a higher prevalence of various autoantibodies has been 
identified in CRPS patients [34–37]; and (3) indications of 
increased T lymphocyte activity have been found in CRPS 
patients [38].
These different sources of inflammation have provided us 
with a few promising biomarkers of inflammation in CRPS. 
Before we discuss these potential biomarkers of inflamma-
tion, however, we discuss the role of subtypes and pheno-
typical characterization in the diagnosis and management 
of CRPS.
3  CRPS: Subtypes and Phenotypes
CRPS has been known by a multitude of names in the past 
due to its varied presentation and ideas on its etiology. In 
1993, a consensus meeting was held by the IASP Task Force 
on Taxonomy to develop a more general and neutral term for 
the symptoms and signs that make up this condition [39, 40]. 
During this meeting, two types of CRPS were recognized: 
CRPS type I, previously known as reflex sympathetic dystro-
phy (RSD), in which there is no demonstrable nerve lesion; 
and CRPS type II, previously known as causalgia, in which 
there is demonstrable nerve lesion during physical examina-
tion and/or on electrodiagnostic testing [39–42]. However, 
these subtypes do not differ in clinical symptoms and signs 
nor in their response to therapy [11]. For the most part, the 
pathophysiological mechanisms also seem to be shared by 
both these subtypes [11]. Therefore, in our practice, this sub-
type distinction is no longer used when diagnosing CRPS, 
and we will use the term CRPS to encompass both these 
subtypes throughout this article.
Bruehl et al. [8, 10] have conducted two cluster analy-
sis studies in which they found that CRPS patients can be 
clustered into different subtypes based on symptoms and 
signs. The first study was conducted in 2002; the authors 
performed a K-means cluster analysis on a group of 113 
CRPS patients and were able to cluster patients into three 
distinct subgroups [8]. Based on their findings, the authors 
proposed the following three subtypes [8]: “(1) a relatively 
limited syndrome with vasomotor signs predominating; (2) 
a relatively limited syndrome with neuropathic pain/sensory 
abnormalities predominating; and (3) a florid CRPS syn-
drome similar to descriptions of Classic RSD”, as described 
by Gibbons and Wilson in 1992 [43]. The second study was 
conducted in 2016; in this study, a two-step cluster analysis 
in a group of 152 CRPS patients provided evidence for a 
warm and cold CRPS subtype [10]. The warm CRPS sub-
type was associated with a more inflammatory phenotype 
with a warm, erythematous, swollen, and sweaty extremity. 
By contrast, the phenotype of the affected extremity in the 
case of cold CRPS was characterized by a colder tempera-
ture, blue or pale skin, and also edema, although this latter 
characteristic was less common than in the warm cluster. 
The authors further showed that differences between these 
CRPS subtypes was based on multiple symptoms and signs 
that showed a consistent covariation across patients, indicat-
ing the possibility of common underlying pathophysiological 
mechanisms that could be targeted by specific therapies [10]. 
For example, the symptoms and signs (i.e., phenotype) typi-
cally associated with the warm CRPS subtype may reflect an 
underlying inflammatory mechanism that could be targeted 
with anti-inflammatory therapies.
The hypothesis that phenotypical characterization in 
CRPS can be used to assess the underlying pathophysi-
ological mechanisms of disease, and consequently to select 
targeted therapies, was presented in an article by Birklein 
and Schlereth in 2015 [9]. The authors described two phe-
notypes of CRPS: the “peripheral inflammatory phenotype” 
reflecting clinical symptoms and signs that are generated by 
inflammation, and the “central neuroplasticity phenotype” 
reflecting clinical symptoms and signs generated by the cen-
tral nervous system (e.g., mechanical allodynia) [9]. The 
problem with phenotypical characterization is, however, that 
clinicians are still dependent on relatively subjective symp-
toms and signs to characterize the subtype of CRPS that a 
patient may have. Another issue to take into consideration 
is the large amount of clinical overlap between the various 
phenotypes and subtypes, which could create confusion 
when determining underlying mechanisms of disease [10]. 
In addition, phenotypical characterization can also misguide 
clinicians to a certain degree. For example, a clinician may 
disregard inflammation as an underlying pathophysiological 
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mechanism in a patient with cold-type CRPS; however, we 
now know from a study in blister fluid that a subgroup of 
cold CRPS patients also suffers from inflammation [44]. 
These issues highlight the need for simple, objective, and 
easily measurable biomarkers in the diagnosis and manage-
ment of CRPS.
In the following sections we discuss potential biomark-
ers of inflammation in CRPS. We start by giving a general 
definition of a biomarker and the criteria that a biomarker 
for CRPS would need to meet. We then discuss potential bio-
markers of inflammation that have been identified in CRPS 
and their possible role in the diagnosis and/or management 
of this disease. Lastly, we provide suggestions for future 
research.
4  Definition of a Biomarker and Criteria 
for CRPS
A biomarker is defined as: “a characteristic that is objec-
tively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention” [45]. Not 
only can a biomarker be used in regard to the response 
to a therapeutic intervention, it can also be used in the 
diagnosis, prognosis, and monitoring of diseases [45]. In 
the case of CRPS, biomarkers could aid in various aspects 
of diagnosis and management: first, they could be used to 
aid the (early) diagnosis of this disease; second, they could 
be used, together with phenotypical characterization, to 
identify the underlying mechanisms of disease for selec-
tion of therapies; and, third, they could be used to monitor 
disease activity and/or effects of therapy. We consider a 
biomarker that can be used in the first two situations as 
applicable in the diagnosis of CRPS, while a biomarker 
that can be used in the third situation is applicable in the 
management of this disease.
Most CRPS patients are treated by pain physicians in an 
outpatient clinic setting with limited access to extensive 
laboratory testing. Taking this into consideration, an ideal 
biomarker for CRPS would need to meet the following 
criteria: (1) the tissue or fluid that is required to determine 
the biomarker needs to be obtained in a simple manner in 
routine practice; (2) the measurement of the biomarker 
needs to be simple and reproducible using routine labora-
tory testing; and (3) the procedure to obtain the biomarker 
needs to be at a minimal risk to the patient, for example, a 
low-risk venipuncture versus a medium-risk skin biopsy.
In the following sections we highlight a few potential 
biomarkers of inflammation in CRPS. In the future, these 
biomarkers could, for example, be used in patients with 
the “warm subtype”, as described by Bruehl et al. [10], or 
the “peripheral inflammatory subtype”, as described by 
Birklein and Schlereth [9], to objectively identify inflam-
mation and to start anti-inflammatory therapies.
For the purpose of simplicity, we have chosen to 
divide the biomarkers into two groups: ‘potential bio-
markers of neurogenic inflammation and neuroinflam-
mation’ and ‘potential biomarkers of immune dysregu-
lation’ (Tables 1 and 2). We have further divided these 
biomarkers into local and systemic biomarkers: local 
biomarkers are markers that are typically measured in 
the affected tissues, while systemic biomarkers are meas-
ured in blood. Both local and systemic biomarkers will 
be further subdivided into soluble and cellular markers 
where possible.
We acknowledge that there is a complex interplay 
between these inflammatory mechanisms and that some, 
if not most, biomarkers can be applied to identify all 
mechanisms.
Table 1  Potential biomarkers of neurogenic inflammation and neuroinflammation in complex regional pain syndrome
CGRP calcitonin gene-related peptide, CRPS complex regional pain syndrome, PET positron emission tomography, SP substance P, + indicates 
a possible role as a biomarker in the diagnosis and/or management of CRPS, ?  indicates that insufficient information is currently available to 
determine a possible role as a biomarker in the diagnosis and/or management of CRPS
a The biomarker aids the (early) diagnosis of this disease and/or it could be used, together with phenotypical characterization, to identify the 
underlying mechanisms of disease for selection of therapies
b The biomarker could be used to monitor disease activity and/or effects of therapy
Biomarkers Cellular or soluble Acquisition Type of inflammation Use in diagnosis  
of CRPS a






Not applicable [11C]-(R)-PK11195-PET Neuroinflammation ? ?
Systemic markers
CGRP Soluble Venous blood Neurogenic + ?
SP Soluble Venous blood Neurogenic ? ?
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5  Potential Biomarkers of Neurogenic 
Inflammation and Neuroinflammation
5.1  Local Biomarkers
Although this article mainly discusses biochemical mark-
ers of inflammation that can be measured in clinical lab-
oratories, we would like to highlight the findings by Jeon 
et al. [21] and Jung et al. [22] regarding neuroinflamma-
tion. Jeon et al. [21] conducted a study in which they used 
 [11C]-(R)-PK11195 positron emission tomography (PET) to 
observe microglial activation in CRPS patients and iden-
tify whether there was an association with symptom sever-
ity. The authors found a significantly higher distribution 
volume ratio (DVR) of  [11C]-(R)-PK11195 in the caudate 
nucleus, putamen, nucleus accumbens, and thalamus of 
CRPS patients than in the healthy controls. They further 
found a statistically significant, positive correlation between 
 [11C]-(R)-PK11195 DVR and pain severity [21]. These find-
ings point towards microglial activation and neuroinflamma-
tion in CRPS with a possible association between degree of 
neuroinflammation and pain severity.
Jung et al. [22] conducted an explorative study in which 
they studied the correlation between peripheral metabo-
lites in blood and urine, central neurometabolites using 
proton magnetic resonance spectroscopy (1H-MRS), and 
neuroinflammation using  [11C]-(R)-PK11195 PET. The 
authors found statistically significant positive correlations 
between the levels of lipid 13a and lipid 09 relative to total 
creatine and neuroinflammation in certain brain regions of 
CRPS patients [22]. They further found that peripheral pH, 
glucose,  CO2, basophil, and creatinine levels were associated 
with an increase or decrease of the level of neuroinflamma-
tion in the brain of CRPS patients [22]. The authors suggest 
that characterization of peripheral and central metabolites 
may help us to understand the role of neuroinflammation 
in the pathophysiology of CRPS. They further suggest 
that central lipid levels may be used as a biomarker for 
neuroinflammation.
The results from these two studies pave the way for a new 
field of research on the role of neuroinflammation in the 
pathophysiology of CRPS. These results, however, need to 
be further analyzed in a clinical context and we cannot yet 
determine the role of these techniques and markers in the 
diagnosis and management of CRPS.
5.2  Systemic Biomarkers
Four studies measured venous blood levels of the soluble neu-
ropeptide CGRP in CRPS patients [32, 46–48]. Blair et al. [46] 
conducted a study in which they measured CGRP levels in the 
blood of CRPS patients and healthy controls: blood CGRP 
Table 2  Potential biomarkers of immune dysregulation in complex regional pain syndrome
CRPS complex regional pain syndrome, IL-6 interleukin-6, miRNA microRNA, sIL-2R soluble interleukin-2 receptor, TNF-α tumor necrosis 
factor-α, + indicates a possible role as a biomarker in the diagnosis and/or management of CRPS, ? indicates that insufficient information is cur-
rently available to determine a possible role as a biomarker in the diagnosis and/or management of CRPS
a The biomarker aids the (early) diagnosis of this disease and/or it could be used, together with phenotypical characterization, to identify the 
underlying mechanisms of disease for selection of therapies
b The biomarker could be used to monitor disease activity and/or effects of therapy
c Autoantibodies studied in CRPS: autoantibodies against autonomic nervous system structures [34], autoantibodies against autonomic nervous 
system autoantigens (e.g., β2-adrenergic receptor and/or muscarinic-2 receptor) [35, 36], and anti-nuclear antibodies [37]
Biomarkers Cellular or soluble Acquisition Use in diagnosis  
of  CRPSa




TNF-α Soluble Blister fluid + +
IL-6 Soluble Blister fluid + +
Tryptase Soluble Blister fluid + +
Mast cell numbers Cellular Skin biopsies + +
Systemic markers
CD14+CD16+ monocytes Cellular Venous blood ? ?
CD8+ T lymphocytes Cellular Venous blood ? ?
sIL-2R Soluble Venous blood + ?
Autoantibodiesc Soluble Venous blood ? ?
miRNA Soluble Venous blood + +
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levels were higher in the patients than in the controls. Birklein 
et al. [47] conducted a study in which they measured serum 
CGRP levels in CRPS patients and age- and gender-matched 
healthy controls. The authors had some interesting findings: 
first, serum CGRP levels were significantly higher in CRPS 
patients than in controls; second, serum CGRP levels did not 
differ between the affected and contralateral limb; third, serum 
CGRP normalized in the group of patients who agreed to a 
follow-up visit at 9 months after the initial assessment—this 
normalization was accompanied by a clinical improvement of 
local inflammatory symptoms, but not a reduction in pain; and, 
fourth, higher serum CGRP levels correlated significantly with 
the incidence of nerve lesions and hyperhidrosis but not with 
pain, CRPS duration, or other clinical symptoms [47]. Schinkel 
et al. [32] conducted two studies in which they assessed blood 
CGRP levels in CRPS patients. In the first study, no difference 
was found in blood CGRP levels between patients with mostly 
acute CRPS and healthy age- and gender-matched controls. 
In the second study, they found significantly lower levels of 
CGRP in the blood of patients with chronic CRPS than healthy 
controls, although the authors state that these differences were 
marginal [48]. Though the results from these studies contra-
dict each other, there may possibly be a role for serum CGRP 
in the diagnosis of an underlying neurogenic mechanism in 
CRPS, especially in patients with sudomotor (sweating) symp-
toms. Based on these findings, we cannot conclude whether 
this marker can be used in the management of this disease. 
Although studies seem to indicate a role for CGRP in CRPS 
[19, 46, 47], CGRP antagonists have, to our knowledge, not yet 
been tested in CRPS patients. However, it is not unthinkable 
that serum CGRP levels could be used in the future to select 
CRPS patients who would benefit from this therapy, if these 
therapies are ever proven effective in this disease.
The two studies by Schinkel et al. [32, 48] also examined 
SP levels in the venous blood of CRPS patients. In the first 
study, the authors found significantly higher SP levels in the 
blood of patients with mostly acute CRPS than in the blood of 
healthy controls [32]. In the second study, the authors found 
higher blood SP levels in CRPS patients than in healthy con-
trols, although this difference was not statistically significant. 
There was, however, a significant difference between acute 
and chronic CRPS, with acute CRPS patients having signifi-
cantly lower levels of SP than chronic CRPS patients [48]. By 
contrast, the study by Blair et al. [46] showed no difference in 
blood SP levels between CRPS patients and healthy controls. 
To our knowledge, these studies did not look at the correlation 
between SP and clinical symptoms [32, 46, 48]. Based on the 
findings from these studies, we cannot determine the place of 
SP in the diagnosis and/or management of CRPS; however, we 
can conclude that there may be a role for SP in the pathophysi-
ology of CRPS.
6  Potential Biomarkers of Immune 
Dysregulation in CRPS
6.1  Local Biomarkers
One of the first studies that proved inflammation plays a 
significant role in CRPS also gave us some of the first sol-
uble local inflammatory biomarkers for this disease [33]. 
In 2002, Huygen et al. [33] conducted a study in which 
they assessed whether changes in levels of inflamma-
tory mediators could be found in limbs of CRPS patients. 
The authors induced artificial skin blisters in the CRPS-
affected and contralateral limb and subsequently extracted 
the fluid from these blisters. They found significantly ele-
vated levels of the pro-inflammatory cytokines TNF-α and 
IL-6 in the affected limbs [33]. Based on these findings, 
their group decided to treat two patients with the TNF-α 
inhibitor infliximab. This treatment resulted in consider-
able clinical improvement in both patients and was associ-
ated with a substantial decline of TNF-α and IL-6 levels in 
blister fluid [49]. These results illustrate that blister-fluid 
TNF-α and IL-6 levels can be considered as local biomark-
ers with two potential applications: firstly, for determining 
the inflammatory component in CRPS, and thus determin-
ing the eligibility of a patient for treatment with a TNF-α 
inhibitor such as infliximab; and, secondly, for monitoring 
treatment response to this TNF-α inhibitor. However, it 
should be noted that randomized controlled trials are still 
required to assess the therapeutic effects of TNF-α inhibi-
tors in CRPS [50].
Another potential local biomarker of inflammation in 
CRPS is the mast cell and its specific mediators. Activated 
mast cells release various mast cell-specific products, 
including tryptase [51, 52]. Significantly higher levels of 
tryptase have been found in blister fluid of the affected 
limb of CRPS patients than in the contralateral limb [53]. 
In addition, blister fluid tryptase levels were found to have 
a significant positive correlation with patient pain scores 
[53]. In further support of a role for mast cells in CRPS are 
the findings by Birklein et al. [54] describing higher mast 
cell numbers in skin biopsies of the affected limb than 
in skin biopsies of the contralateral limb. Interestingly, 
mast cell numbers seem to be increased only in the early 
stages of CRPS and not in long-standing disease [54, 55]. 
Consequently, determining local mast cells could represent 
a diagnostic biomarker of inflammation associated with 
early-stage CRPS. If elevated mast cell numbers or specific 
mast cell products are found, mast cell-directed therapy 
could be considered [56, 57] and determining local mast 
cell accumulation or their products (e.g., tryptase) could 
be used to monitor treatment effect.
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6.2  Systemic Biomarkers
Circulating monocytes can be subdivided into three phe-
notypically distinct subpopulations based on the expres-
sion of CD14 and CD16, i.e.,  CD14+CD16− monocytes, 
 CD14+CD16+ monocytes, and  CD14+/−CD16++ mono-
cytes [58, 59]. The monocyte subset composition is altered 
in peripheral blood in the case of inflammatory diseases, 
with mostly an increased fraction of the pro-inflammatory 
 CD14+CD16+ monocytes (also designated as intermediate 
monocytes) [59, 60]. Moreover, in sarcoidosis, for instance, 
the relative abundance of circulating  CD14+CD16+ mono-
cytes has been found to correlate positively with serum 
angiotensin-converting enzyme (ACE) levels of patients, 
suggesting that it represents a marker for disease activity 
[61]. In CRPS patients, an elevated fraction of pro-inflam-
matory  CD14+CD16+ monocytes in venous blood has also 
been observed in comparison with healthy controls [62]. 
 CD14+CD16+ monocytes are poor producers of the anti-
inflammatory cytokine IL-10 as compared to the classical 
 CD14+CD16− monocytes, whereas both monocyte sub-
populations produce similar amounts of pro-inflammatory 
cytokines [62, 63]. These findings suggest that the increase 
in  CD14+CD16+ monocytes in CRPS may contribute to and 
reflect a pro-inflammatory status [62]. Moreover, the study 
by Ritz et al. [62] observed a positive correlation between 
the relative abundance of the  CD14+CD16+ monocyte sub-
set and the clinical sign of cold allodynia, which can indi-
cate a role of these monocytes in the development of central 
sensitization in CRPS patients. When interpreted with cau-
tion, there might be a diagnostic role for monocyte subset 
determination in the assessment of the inflammatory status 
and central sensitization in CRPS patients. However, further 
research into this topic is clearly needed as it is not clear 
whether these pro-inflammatory monocytes have a patho-
genic quality or are merely a result of an already ongoing 
inflammatory process in CRPS. Additionally, monocytes 
that infiltrate tissues differentiate further into macrophages, 
of which different subtypes exist; future research on the rela-
tive tissue distribution of these pro-inflammatory M1 and 
anti-inflammatory M2 macrophages in CRPS could thus also 
be of interest [64, 65].
Circulating T  lymphocyte subsets represent another 
example of potential cellular biomarkers in CRPS. To our 
knowledge, three studies have determined T lymphocyte 
subsets in venous blood of CRPS patients [31, 62, 66]. These 
studies, however, show conflicting results when it comes to 
alterations in circulating T lymphocyte subsets. For example, 
while Kaufmann et al. [66] found significantly lower abso-
lute numbers of cytotoxic  CD8+ T lymphocytes in CRPS 
patients than in healthy controls, Ribbers et al. [31] observed 
no difference in the absolute numbers of this subset, and Ritz 
et al. [62] found no difference in the percentage of this subset 
between CRPS patients and healthy controls. Interestingly, 
Kaufmann et al. [66] did not find any correlation between 
 CD8+ T lymphocytes and pain, as measured on a Visual 
Analog Scale ranging from 0 to 10 in CRPS patients. Based 
on these conflicting results, we cannot draw a conclusion 
on whether T lymphocyte subset measurement in peripheral 
blood can currently be used as a biomarker for diagnosis 
and/or management of CRPS. Yet the existence of many 
different T lymphocyte subsets, including different types of 
T helper subsets, clearly warrants further study into the rela-
tion between T lymphocytes and CRPS [67, 68].
Not only can T lymphocyte involvement be assessed at 
a cellular level, but it can also be assessed using a soluble 
marker for T lymphocyte activity [69]. The soluble IL-2 
receptor (sIL-2R), also termed CD25, is a truncated protein 
that is released from activated T cells: hence, it is a surrogate 
marker for T cell activation [69, 70]. Peripheral blood levels 
of the sIL-2R thus reflect the level of T cell activation in 
an individual and elevated blood levels of sIL-2R correlate 
with disease activity in, for instance, rheumatoid arthritis, 
systemic lupus erythematosus, and sarcoidosis, diseases in 
which enhanced T cell activity is centrally involved [71–75]. 
Our group measured sIL-2R serum levels in CRPS patients 
and compared this to the serum sIL-2R levels of healthy con-
trols [38]. We found significantly higher levels of the sIL-
2R in CRPS patients than in healthy controls [38]. Serum 
sIL-2R further seems to be a good discriminator between 
patients with CRPS and healthy controls, showing a high 
sensitivity (90%) and specificity (89.5%) [38]. These results 
seem promising: firstly, they may be indicative of a role for 
pathogenic T lymphocyte activation in CRPS, and, secondly, 
they could lead to the use of the sIL-2R as a biomarker in 
the diagnosis and/or management of CRPS. However, the 
place of this marker in the diagnosis and/or management 
of this disease is yet to be determined and we are currently 
validating these findings in further studies.
Autoantibodies represent another example of soluble bio-
markers. Autoantibodies are commonly used as biomarkers 
for diagnosis and monitoring of inflammatory diseases and 
autoimmune diseases [76]. Multiple studies have described 
various autoantibodies in CRPS [34–37]. One study identi-
fied autoantibodies against autonomic nervous system struc-
tures in a small subset of CRPS patients: five of 12 CRPS 
patients were positive for these autoantibodies [34]. Another 
study found that ~ 30 to 40% of their CRPS patient group 
had autoantibodies against an autonomic nervous system 
autoantigen [35]. In a follow-up study, this group aimed to 
identify the antigens targeted by these autoantibodies and 
found agonistic autoantibodies against the β2-adrenergic 
receptor and/or the muscarinic-2 receptor in a subset of their 
CRPS patients [36]. A third study found a higher prevalence 
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of anti-nuclear antibody positivity in CRPS patients than 
in healthy controls (33% vs. 4%; p < 0.001) [37]. Although 
these data support involvement of an autoimmune compo-
nent in CRPS, it is still unclear whether these autoantibodies 
are pathogenic or a result of this disease. Consequently, their 
role as biomarkers in the diagnosis and/or management of 
CRPS needs further evaluation, especially in comparison 
with other diseases that are included in the initial differential 
diagnosis.
Finally, we would like to highlight the potential role of 
systemic microRNAs (miRNAs) in the diagnosis and man-
agement of CRPS [77]. miRNAs are small non-coding RNA 
molecules that suppress protein synthesis through messenger 
RNA (mRNA) silencing [78, 79]. Orlova et al. [80] have 
suggested the potential application of blood miRNA profil-
ing in the selection of treatments for CRPS patients and in 
the stratification of CRPS patients in, for example, clinical 
trials [80]. They compared blood miRNA profiles of CRPS 
patients with those of healthy controls and found a sig-
nificant differential expression of 18 miRNAs in the CRPS 
group [80]. They were further able to stratify the study popu-
lation into three clusters, with one cluster containing 60% of 
the CRPS patients and no healthy controls. Further analysis 
of this CRPS-only cluster revealed significant alterations in 
additional miRNAs and inflammatory markers compared 
to the rest of the CRPS patients and healthy controls [80]. 
Though the clinical relevance is still not clear, these findings 
suggest that differentially expressed miRNAs could help to 
identify different CRPS subtypes and could further lead to 
the identification of additional inflammatory markers that 
are specific to these subtypes [77, 80]. In addition, miRNA 
profiling could also be used as a prognostic biomarker to 
identify responders to specific therapies [81]. Thus, the 
application of miRNA profiling could be useful in the diag-
nosis as well as the management of CRPS; however, research 
on this subject is still in its initial phase and more research 
is needed to validate current results.
7  Biomarkers in CRPS: Limitations, 
Considerations, and Recommendations 
for Future Research
Although the findings already mentioned are promising, to 
date no biomarkers that have been implemented in the rou-
tine clinical practice surrounding CRPS patients. It is clear 
that we still have a long path ahead when it comes to the 
identification, validation, and application of biomarkers in 
the diagnosis and management of CRPS. As this disease is 
currently diagnosed using a set of relatively subjective clini-
cal criteria, an objective biomarker would be welcomed with 
open arms by pain physicians. There are, however, matters to 
be considered when choosing a biomarker (Table 3).
First, acquisition of the marker is of great importance: 
is it acquired locally or systemically? Some of the markers 
mentioned earlier are acquired in blister fluid and/or skin 
biopsies while others are measured in venous blood. The 
techniques for skin blisters and skin biopsies are considered 
to be of a higher risk to the patient and more invasive than a 
venipuncture and require a close follow-up to assess healing 
of the damaged skin. The skin blister technique is also time 
consuming and requires pain physicians to have access to 
materials and devices not usually available in routine prac-
tice [33]. Second, is it simple to obtain in routine practice? 
Table 3  An overview of the discussed biochemical biomarkers of inflammation in complex regional pain syndrome together with an overview of 
considerations for routine practice
CGRP calcitonin gene-related peptide, IL-6 interleukin-6, miRNA microRNA, sIL-2R soluble interleukin-2 receptor, SP substance  P, TNF-α 
tumor necrosis factor-α, + indicates ‘yes’, − indicates ‘no’
Biomarker Acquisition Simple to obtain in routine 
practice
Easy to measure Minimal 
risk to 
patient
CGRP Venous blood + + +
SP Venous blood + + +
TNF-α Blister fluid − + −
IL-6 Blister fluid − + −
Tryptase Blister fluid − + −
Mast cell numbers Skin biopsies − − −
CD14+CD16+ monocytes Venous blood + + +
CD8+ T lymphocytes Venous blood + + +
sIL-2R Venous blood + + +
Autoantibodies Venous blood + +/− +
miRNA Venous blood + − +
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In general, a marker that can be measured in venous blood is 
easier to obtain in routine practice than a marker that needs 
to be measured in skin biopsies or blister fluid. Furthermore, 
certain techniques require training. Pain physicians would 
thus need to be trained in obtaining skin biopsies and induc-
ing artificial skin blisters. Third, is the biomarker easy to 
measure? This question is largely dependent on whether 
an affiliated laboratory has the facilities to determine the 
aforementioned markers; for example, an enzyme-linked 
immunosorbent assay (ELISA) is a relatively simple tech-
nique to quantify substances such as autoantibodies, while 
a cell-based assay is a more complex technique that is often 
not routinely available. Lastly, and most importantly, does it 
pose a minimal risk to the patient? Patients with CRPS have 
continuing pain of the affected limb that can be worsened by 
touch or any form of contact (allodynia and/or hyperalgesia). 
Performing a skin biopsy or inducing a skin blister in the 
affected limb can temporarily increase the pain a patient is 
experiencing. In contrast, venipuncture is usually conducted 
in the contralateral limb, or, in the case of the lower limb, in 
an arm, thereby avoiding the painful limb.
We are aware that biomarkers of inflammation can also 
be detected in other tissues and fluids, for instance in cer-
ebrospinal fluid (CSF) [82–84]. However, we chose not to 
include findings in CSF as the technique to acquire this fluid, 
a lumbar puncture, is quite invasive and currently only used 
in a research setting in CRPS. Furthermore, we chose to 
cover (mostly) biochemical and cellular markers of inflam-
mation in CRPS; however, biomarkers are not only limited 
to biochemical or cellular findings but can also be clinical or 
radiographic in nature. In the future, it would be interesting 
to review all these different forms of biomarkers in CRPS.
In addition to the biomarkers discussed in this article, 
future research on the identification of other potential bio-
markers of inflammation in CRPS is indicated. A molecule 
of interest is, for instance, the high mobility group box 1 
(HMGB1) protein, a ligand for multiple immune receptors, 
that has been implicated in neuropathic pain and in various 
inflammatory diseases [85, 86]. To our knowledge, HMGB1 
has not yet been measured in CRPS patients. Furthermore, 
genetic and epigenetic analysis may represent an interesting 
future field of research, not only for identification of bio-
markers but also to enhance our pathogenetic understanding 
of CRPS.
Future research should also focus on other non-invasive 
options for detection of biomarkers in CRPS, for instance 
salivary analysis [87]. To our knowledge, only one study 
has used salivary analysis to analyze whether free radicals 
and oxidative stress are involved in the pathophysiology of 
CRPS [88]. Although further optimization and validation of 
this approach for detection of most inflammatory markers 
is required [87], it may represent a promising method for 
non-invasive monitoring of inflammatory markers that war-
rants further exploration in CRPS.
While writing this article, we noticed that most biomark-
ers of inflammation that we have described have not yet been 
correlated with clinical symptoms and signs and thus a spe-
cific subtype or phenotype of CRPS. Future research should 
thus focus on identifying correlations between potential bio-
markers of inflammation and clinical symptoms and signs 
of CRPS. Furthermore, validation studies are needed before 
any of the described markers can be implemented as routine 
biomarkers in the diagnosis and management of CRPS. In 
addition, considering the multi-mechanism pathophysiology 
of CRPS, it would be interesting for future studies to inves-
tigate biomarkers that could identify the other pathophysi-
ological mechanisms of disease in CRPS.
8  Conclusions
The importance of identification and validation of biomark-
ers in CRPS lies in the objective quality they bring to both 
the diagnosis and management of this disease. In the case of 
biomarkers of inflammation in CRPS, they can potentially be 
used to (1) diagnose patients with CRPS; (2) aid phenotypi-
cal characterization in identifying underlying inflammatory 
mechanisms; (3) stratify patients according to who would or 
would not benefit from anti-inflammatory therapies; and (4) 
monitor the effects of these therapies.
Although there are a number of promising biomarkers 
of inflammation described in CRPS, it is still difficult to 
determine the place of these markers in the diagnosis and 
management of CRPS based on the current literature. Future 
studies should focus on finding correlations between clinical 
symptoms and signs and these biomarkers.
As CRPS is a multi-mechanism disease, we currently do 
not believe that there will be one biomarker specific to this 
disease. We believe that in the future, multiple biomarkers 
will be used together with phenotypical characterization to 
identify which mechanisms are prominent in each CRPS 
case. The results will then be used to guide physicians in the 
diagnosis and management of CRPS.
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